Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II GISL study of R-HyperCVAD for mantle cell lymphoma
2005-001500-39Phase 2Completed
- Sponsor
- Gruppo Italiano Studio Linfomi
- Start
- Aug 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in mantle cell lymphoma (MCL), sponsored by Gruppo Italiano Studio Linfomi. Primary endpoint: Complete response rate. Started Aug 2007; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2005-001500-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001500-39.